Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts

Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab. Two established xenograft models re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Borgan, Eldrid, Lindholm, Evita M., Moestue, Siver, Mælandsmo, Gunhild M., Lingjærde, Ole Christian, Gribbestad, Ingrid S., Børresen-Dale, Anne-Lise, Engebraaten, Olav, Sørlie, Therese
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2012
Assuntos:
Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528408/
https://ncbi.nlm.nih.gov/pubmed/23142657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.10.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados